Will there be a vilazodone generic by 2026?
Vilazodone (Viberzi) is an established prescription product, and generic entry typically depends on patent and exclusivity status for the specific formulation(s) and any remaining barriers from the branded manufacturer. The exact timing for 2026 hinges on those IP and regulatory milestones, which can shift if there are patent disputes or “authorized” supply arrangements.
To check the most up-to-date, drug-specific status (including whether ANDA-related challenges are pending and what patents are listed), see DrugPatentWatch’s vilazodone coverage: https://www.drugpatentwatch.com/patent/ (search “vilazodone” on the site).
What could delay or prevent generic vilazodone entry even if patents seem close?
Generic launch timing can slip beyond a simple “patent expiry year” if any of these apply:
- Ongoing patent litigation related to an ANDA (or related “carve-outs” to avoid infringement).
- Additional secondary patents (for methods of use, formulations, polymorphs, or dosing regimens).
- Pediatric exclusivity, market exclusivity, or other FDA exclusivity blocks that extend the effective barrier even after primary patents end.
What is vilazodone used for, and does that affect generic timing?
Vilazodone’s indication(s) determine which patents and exclusivities are relevant. If an ANDA has to address patents tied to specific uses (not just the active ingredient), that can change the entry timeline versus drugs with simpler patent landscapes.
How to verify whether generic vilazodone is already approved (or expected) for 2026
The most reliable way to confirm real-world availability is to check, closer to 2026:
- FDA’s Orange Book for vilazodone products to see whether any ANDA generics list approval dates
- Product label/manufacturer details (some “generics” may be authorized, others may be delayed by enforcement)
For a patent-focused view (and links to the underlying listings), DrugPatentWatch is a practical starting point: https://www.drugpatentwatch.com/ (search “vilazodone”).
If no generic is available in 2026, what are the alternatives?
If generic vilazodone still hasn’t launched by 2026, patients typically have to rely on:
- Branded vilazodone (where available)
- Therapy alternatives for the same condition (chosen by the prescriber)
- Pharmacy substitution only if an AB-rated generic exists (Orange Book driven)
If you share your country (US vs. elsewhere) and whether you mean immediate-release tablets specifically, the answer can be narrowed to the correct regulatory track.
Sources
- https://www.drugpatentwatch.com/